The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
Shibani Nicum
No relevant relationships to disclose
Claire E Brooks
No relevant relationships to disclose
Rose Wharton
No relevant relationships to disclose
Lucy Boyle
No relevant relationships to disclose
Stanley B. Kaye
No relevant relationships to disclose
Charlie Gourley
Research Funding - AstraZeneca
Marcia Hall
No relevant relationships to disclose
Ana Montes
No relevant relationships to disclose
Sarah R Pearson
No relevant relationships to disclose
Patrick Julier
No relevant relationships to disclose
Rachel A Midgley
No relevant relationships to disclose
Anna Schuh
Honoraria - Celgene; GlaxoSmithKline; Roche
Susan J. Dutton
No relevant relationships to disclose